These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 16888228

  • 1. Characterization of the new photoaffinity probe (Bz2-K24)-VIP.
    Tan YV, Couvineau A, Lacapere JJ, Laburthe M.
    Ann N Y Acad Sci; 2006 Jul; 1070():575-80. PubMed ID: 16888228
    [Abstract] [Full Text] [Related]

  • 2. Spatial approximation between the C-terminus of VIP and the N-terminal ectodomain of the VPAC1 receptor.
    Ceraudo E, Tan YV, Couvineau A, Lacapere JJ, Laburthe M.
    Ann N Y Acad Sci; 2006 Jul; 1070():180-4. PubMed ID: 16888162
    [Abstract] [Full Text] [Related]

  • 3. The human VPAC1 receptor: identification of the N-terminal ectodomain as a major VIP-binding site by photoaffinity labeling and 3D modeling.
    Couvineau A, Tan YV, Ceraudo E, Lacapère JJ, Murail S, Neumann JM, Laburthe M.
    Ann N Y Acad Sci; 2006 Jul; 1070():205-9. PubMed ID: 16888167
    [Abstract] [Full Text] [Related]

  • 4. Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction.
    Ceraudo E, Hierso R, Tan YV, Murail S, Rouyer-Fessard C, Nicole P, Robert JC, Jamin N, Neumann JM, Robberecht P, Laburthe M, Couvineau A.
    FASEB J; 2012 May; 26(5):2060-71. PubMed ID: 22291440
    [Abstract] [Full Text] [Related]

  • 5. VPAC1 receptor binding site: contribution of photoaffinity labeling approach.
    Couvineau A, Ceraudo E, Tan YV, Laburthe M.
    Neuropeptides; 2010 Apr; 44(2):127-32. PubMed ID: 20031208
    [Abstract] [Full Text] [Related]

  • 6. Diffuse pharmacophoric domains of vasoactive intestinal peptide (VIP) and further insights into the interaction of VIP with the N-terminal ectodomain of human VPAC1 receptor by photoaffinity labeling with [Bpa6]-VIP.
    Tan YV, Couvineau A, Laburthe M.
    J Biol Chem; 2004 Sep 10; 279(37):38889-94. PubMed ID: 15247290
    [Abstract] [Full Text] [Related]

  • 7. The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics.
    Ceraudo E, Murail S, Tan YV, Lacapère JJ, Neumann JM, Couvineau A, Laburthe M.
    Mol Endocrinol; 2008 Jan 10; 22(1):147-55. PubMed ID: 17885205
    [Abstract] [Full Text] [Related]

  • 8. Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor.
    Tan YV, Couvineau A, Van Rampelbergh J, Laburthe M.
    J Biol Chem; 2003 Sep 19; 278(38):36531-6. PubMed ID: 12807902
    [Abstract] [Full Text] [Related]

  • 9. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
    Marie JC, Rouyer-Fessard C, Couvineau A, Nicole P, Devaud H, El Benna J, Laburthe M.
    Mol Pharmacol; 2003 Dec 19; 64(6):1565-74. PubMed ID: 14645688
    [Abstract] [Full Text] [Related]

  • 10. Asn229 in the third helix of VPAC1 receptor is essential for receptor activation but not for receptor phosphorylation and internalization: comparison with Asn216 in VPAC2 receptor.
    Nachtergael I, Gaspard N, Langlet C, Robberecht P, Langer I.
    Cell Signal; 2006 Dec 19; 18(12):2121-30. PubMed ID: 16650965
    [Abstract] [Full Text] [Related]

  • 11. Mutations in the carboxy-terminus of the third intracellular loop of the human recombinant VPAC1 receptor impair VIP-stimulated [Ca2+]i increase but not adenylate cyclase stimulation.
    Langer I, Robberecht P.
    Cell Signal; 2005 Jan 19; 17(1):17-24. PubMed ID: 15451021
    [Abstract] [Full Text] [Related]

  • 12. Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
    Vertongen P, Langlet C, Langer I, Gaspard N, Robberecht P.
    Peptides; 2004 Nov 19; 25(11):1943-9. PubMed ID: 15501526
    [Abstract] [Full Text] [Related]

  • 13. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M, Muciaccia B, Morelli MB, Stefanini M, Cecconi S, Canipari R.
    Reproduction; 2007 Aug 19; 134(2):281-92. PubMed ID: 17660238
    [Abstract] [Full Text] [Related]

  • 14. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
    Dong M, Liu G, Pinon DI, Miller LJ.
    Biochemistry; 2005 May 03; 44(17):6693-700. PubMed ID: 15850403
    [Abstract] [Full Text] [Related]

  • 15. Effect of positive charge in VIP 16gamma-glutamyl diamino derivatives on hVPAC1 and hVPAC2 receptor function.
    de Maria S, Metafora V, Metafora S, Ravagnan G, Cartení M, Pontoni G, Facchiano A, Lepretti M, Severino B, Caliendo G, Santagada V, Langer I, Robberecht P.
    J Pept Sci; 2008 Jan 03; 14(1):102-9. PubMed ID: 17883247
    [Abstract] [Full Text] [Related]

  • 16. Tryptophan 67 in the human VPAC(1) receptor: crucial role for VIP binding.
    Nicole P, Maoret JJ, Couvineau A, Momany FA, Laburthe M.
    Biochem Biophys Res Commun; 2000 Sep 24; 276(2):654-9. PubMed ID: 11027527
    [Abstract] [Full Text] [Related]

  • 17. The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor.
    Ceraudo E, Tan YV, Nicole P, Couvineau A, Laburthe M.
    J Mol Neurosci; 2008 Nov 24; 36(1-3):245-8. PubMed ID: 18597186
    [Abstract] [Full Text] [Related]

  • 18. Presence of a N-terminal signal peptide in class II G protein-coupled receptors: crucial role for expression of the human VPAC1 receptor.
    Couvineau A, Rouyer-Fessard C, Laburthe M.
    Regul Pept; 2004 Dec 15; 123(1-3):181-5. PubMed ID: 15518910
    [Abstract] [Full Text] [Related]

  • 19. Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors.
    Igarashi H, Ito T, Mantey SA, Pradhan TK, Hou W, Coy DH, Jensen RT.
    J Pharmacol Exp Ther; 2005 Oct 15; 315(1):370-81. PubMed ID: 15994369
    [Abstract] [Full Text] [Related]

  • 20. Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency.
    Langer I, Gregoire F, Nachtergael I, De Neef P, Vertongen P, Robberecht P.
    Peptides; 2004 Feb 15; 25(2):275-8. PubMed ID: 15063009
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.